% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Jansen:285464,
author = {Jansen, Robin and Wagenhäuser, Markus U and Kölsche,
Tristan and Papasimos, Cleopatra and Benkert, Pascal and
Kuhle, Jens and Pawlitzki, Marc and Masanneck, Lars and
Schreiber, Stefanie and Caspers, Julian and Ruck, Tobias and
Hagler, Ramona and Stassen, Malin and Weiss, Daniel and
Arndt, Philipp and Dörner, Marc and Mulorz, Joscha and
Meuth, Sven G and Schelzig, Hubert and Lee, John-Ih and
Gliem, Michael},
title = {{S}erum levels of neurofilament light chain ({N}f{L}) and
glial fibrillary acid protein ({GFAP}) in patients with
asymptomatic and symptomatic carotid artery stenosis.},
journal = {JVS-vascular science},
volume = {7},
issn = {2666-3503},
address = {[Amsterdam]},
publisher = {Elsevier},
reportid = {DZNE-2026-00242},
pages = {100408},
year = {2026},
abstract = {The treatment of carotid artery stenosis (CAS) for stroke
prevention is a matter of debate due to conflicting data,
missing recent data, and advances in medical treatment
options but also in interventional techniques and surgery.
Therefore, the establishment of an easily available marker
for brain damage might be a key tool in this patient group
to guide treatment.A retrospective cross-sectional study was
conducted leveraging a vascular surgery biobank of 95
patients aged 60 to 80 years. Serum neurofilament light
chain (sNfL) and serum glial fibrillary acid protein (sGFAP)
were evaluated using highly sensitive
electrochemiluminescence immunoassays and z-scores.
Discriminatory performance was assessed to differentiate
between 19 symptomatic and 76 asymptomatic patients with CAS
and their correlation with the degree of stenosis according
to ultrasound-based North American Symptomatic Carotid
Endarterectomy Trial (NASCET) criteria.SNfL levels were
markedly elevated in symptomatic compared with asymptomatic
patients (median 17.4 vs 3.8 pg/mL; P < .001). sNfL robustly
discriminated between these patients (area under the curve =
0.83; $95\%$ confidence interval, 0.72-0.94), as did the NfL
z-score (area under the curve = 0.83; $95\%$ confidence
interval, 0.71-0.95). Interestingly, within the asymptomatic
cohort, sNfL levels demonstrated a significant, positive
correlation with the degree of stenosis (Spearman's ρ =
0.24; P = .036). Serum levels of SGFAP were also associated
with symptomatic status, albeit with a P-value >.05 (0.1 vs
0.1 pg/mL; (P = .057).The study provides evidence of
increased sNfL in symptomatic vs asymptomatic CAS and, of
note, of ongoing neuronal or glial damage in some patients
with clinically asymptomatic CAS, with a positive
correlation between sNfL and the degree of CAS. sNfL is a
promising and already accessible blood biomarker that may
guide therapeutic decisions in this patient population. The
role of sGFAP remains elusive and must be evaluated in
larger studies.The CREST-2 trial has recently highlighted
the high efficacy of intensive medical management in
asymptomatic carotid artery stenosis (CAS), making the
selection of patients for revascularization increasingly
complex. Our study addresses this challenge by evaluating
serum neurofilament light chain (sNfL) and serum glial
fibrillary acid protein (sGFAP) as an objective biomarker
for neuronal injury. Using individualized z-scores, we
demonstrate that sNfL effectively differentiates symptomatic
status (area under the curve = 0.828) and significantly
correlates with the degree of stenosis in asymptomatic
cohorts. These results suggest that sNfL can detect
subclinical 'silent' damage, providing a valuable biological
tool to pinpoint high-risk patients who may require
intervention beyond medical therapy alone. This represents a
significant step toward personalized stroke prevention and
refined risk stratification in the highly debated field of
CAS management.},
keywords = {Asymptomatic carotid artery stenosis (Other) / Risk
stratification (Other) / Serum biomarker (Other) / Serum
glial fibrillary acid protein (Other) / Serum neurofilament
light chain (Other) / Stroke (Other) / Ultrasound (Other)},
cin = {AG Schreiber},
ddc = {610},
cid = {I:(DE-2719)1310010},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41783480},
pmc = {pmc:PMC12954281},
doi = {10.1016/j.jvssci.2026.100408},
url = {https://pub.dzne.de/record/285464},
}